Compare Crispr Therapeutics AG (CRSP) vs Snowflake Inc (SNOW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Snowflake Inc — how do they compare? Crispr Therapeutics AG trades at $50.54 (market cap $4.97B), while Snowflake Inc trades at $276.46 (market cap $95.64B). The key difference: Snowflake Inc is far larger — about 19.2× Crispr Therapeutics AG's market cap, and Snowflake Inc is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals.
| CRSP | SNOW | |
|---|---|---|
Market Cap | $4.97B | $95.64B |
Sector | Health | Technology |
52-Week High | $76.78 | $280.16 |
52-Week Low | $44.34 | $121.11 |
Enterprise Value | $3.32B | $95.46B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
Snowflake (SNOW) trades at $268.65, up 2.75% with strong technical momentum and bullish moving average signals. The company demonstrates robust revenue growth, reaching $3.63 billion in 2025, though remains unprofitable with a -23.79% net margin. Recent quarterly earnings consistently beat expectations, with Q1 2026 EPS of $0.39 surpassing the $0.3193 estimate. Analyst sentiment remains overwhelmingly positive with 42 buy ratings and a $297.35 consensus price target, representing 10.7% upside potential.
Snowflake's outlook remains promising due to accelerating AI Data Cloud adoption and 30% revenue growth targets, but faces risks from premium valuation (P/S 18.19), intense cloud competition, and persistent profitability challenges. The stock's current technical positioning near pivot point resistance at $269 requires monitoring for breakout confirmation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Snowflake Inc
Founded in 2012, Snowflake is a data lake, warehousing, and sharing company that came public in 2020. To date, the company has over 3,000 customers including nearly 30% of the Fortune 500 as its customers. Snowflake's data lake stores unstructured and semistructured data that can then be used in analytics to create insights stored in its data warehouse. Snowflake's data sharing capability allows enterprises to easily buy and ingest data almost instantaneously compared with a traditionally months-long process. Overall, the company is known for the fact that all of its data solutions that can be hosted on various public clouds.
Read more on SNOW →
